1. Home
  2. IRD vs NRT Comparison

IRD vs NRT Comparison

Compare IRD & NRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • NRT
  • Stock Information
  • Founded
  • IRD 2018
  • NRT 1975
  • Country
  • IRD United States
  • NRT United States
  • Employees
  • IRD N/A
  • NRT N/A
  • Industry
  • IRD
  • NRT Oil & Gas Production
  • Sector
  • IRD
  • NRT Energy
  • Exchange
  • IRD NYSE
  • NRT Nasdaq
  • Market Cap
  • IRD 36.0M
  • NRT 43.7M
  • IPO Year
  • IRD N/A
  • NRT N/A
  • Fundamental
  • Price
  • IRD $1.13
  • NRT $4.76
  • Analyst Decision
  • IRD Strong Buy
  • NRT
  • Analyst Count
  • IRD 1
  • NRT 0
  • Target Price
  • IRD $8.00
  • NRT N/A
  • AVG Volume (30 Days)
  • IRD 150.5K
  • NRT 39.6K
  • Earning Date
  • IRD 02-24-2025
  • NRT 02-25-2025
  • Dividend Yield
  • IRD N/A
  • NRT 9.87%
  • EPS Growth
  • IRD N/A
  • NRT N/A
  • EPS
  • IRD N/A
  • NRT 0.55
  • Revenue
  • IRD $8,381,000.00
  • NRT $5,855,685.00
  • Revenue This Year
  • IRD N/A
  • NRT N/A
  • Revenue Next Year
  • IRD $29.37
  • NRT N/A
  • P/E Ratio
  • IRD N/A
  • NRT $8.65
  • Revenue Growth
  • IRD N/A
  • NRT N/A
  • 52 Week Low
  • IRD $0.81
  • NRT $3.88
  • 52 Week High
  • IRD $2.71
  • NRT $8.62
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • NRT 51.72
  • Support Level
  • IRD N/A
  • NRT $4.56
  • Resistance Level
  • IRD N/A
  • NRT $5.08
  • Average True Range (ATR)
  • IRD 0.00
  • NRT 0.26
  • MACD
  • IRD 0.00
  • NRT -0.01
  • Stochastic Oscillator
  • IRD 0.00
  • NRT 47.37

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About NRT North European Oil Royality Trust

North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.

Share on Social Networks: